Mankind Pharma Ltd
NSE:MANKIND
Intrinsic Value
Mankind Pharma Ltd. engages in the development, manufacture, and marketing of pharmaceutical formulations across acute and chronic therapeutic areas. [ Read More ]
The intrinsic value of one MANKIND stock under the Base Case scenario is 1 420.6 INR. Compared to the current market price of 2 249.2 INR, Mankind Pharma Ltd is Overvalued by 37%.
Valuation Backtest
Mankind Pharma Ltd
Run backtest to discover the historical profit from buying and selling MANKIND stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Mankind Pharma Ltd
Mankind Pharma Ltd
Earnings Waterfall
Mankind Pharma Ltd
|
Revenue
|
87.5B
INR
|
|
Cost of Revenue
|
-30.7B
INR
|
|
Gross Profit
|
56.8B
INR
|
|
Operating Expenses
|
-40.9B
INR
|
|
Operating Income
|
15.9B
INR
|
|
Other Expenses
|
-3.1B
INR
|
|
Net Income
|
12.8B
INR
|
Free Cash Flow Analysis
Mankind Pharma Ltd
MANKIND Profitability Score
Profitability Due Diligence
Mankind Pharma Ltd's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
Score
Mankind Pharma Ltd's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
MANKIND Solvency Score
Solvency Due Diligence
Mankind Pharma Ltd's solvency score is 79/100. The higher the solvency score, the more solvent the company is.
Score
Mankind Pharma Ltd's solvency score is 79/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MANKIND Price Targets Summary
Mankind Pharma Ltd
According to Wall Street analysts, the average 1-year price target for MANKIND is 2 119.64 INR with a low forecast of 1 767.5 INR and a high forecast of 2 488.5 INR.
Shareholder Return
MANKIND Price
Mankind Pharma Ltd
| Average Annual Return |
N/A
|
| Standard Deviation of Annual Returns |
N/A
|
| Max Drawdown | -9% |
| Market Capitalization | 901B INR |
| Shares Outstanding | 401 202 500 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Mankind Pharma Ltd. engages in the development, manufacture, and marketing of pharmaceutical formulations across acute and chronic therapeutic areas. The company is headquartered in New Delhi, Delhi and currently employs 18,468 full-time employees. The company went IPO on 2023-05-09. The firm is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. The company has a portfolio of formulations in several therapeutic areas, such as anti-infectives, cardiovascular, gastrointestinal, vitamins/minerals/nutrients, respiratory, anti-diabetic, dermatology, gynecology, and pain/analgesics, among others. Its other therapeutic areas include urology, ophthalmology, antiparasitic, stomatological, antineoplastic/immunomodulator, hepatoprotective, anti-malarial, blood-related, hormones, antiviral, sex stimulants/rejuvenators, anti-tuberculosis, parenteral and vaccines. Its portfolio of brands includes Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, Dynaglipt, and others.
Contact
IPO
Employees
Officers
The intrinsic value of one MANKIND stock under the Base Case scenario is 1 420.6 INR.
Compared to the current market price of 2 249.2 INR, Mankind Pharma Ltd is Overvalued by 37%.
You don't have any saved screeners yet
